Our product is a biosimilar of Cetuximab (205923-56-4), which is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). This biosimilar is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa, which is produced in mammalian (Chinese Hamster Ovary) cell culture.
Features and Advantages:
NameBiosimilar of Cetuximab
CAS NO.205923-56-4
TypeWhole antibody
SourceChimeric (mouse/human)
TargetEGF receptor
CloneMonoclone
FormulaC6484H10042N1732O2023S36
Molecular Weight152 kDa
Antibody FormPurified immunoglobulin
Physical FormSolution
Place of OriginChina (Mainland)
StorageSealed and stored at -70±15℃, away from light
Specifications:
The concentration of The biosimilar of Cetuximab is 2 mg/mL, and the buffer formulation is consistent with the original preparation (Erbitux®).In addition, the product concentration and buffer system can be customized according to customer requirements. The annual production of the product is about 80-160kgs, the minimum order quantity is 1 gram.
Applications:
Cetuximab, the trade name Erbitux®, is a medication used to treat metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.
The formulation and filling of the biosimilar of Cetuximab bulk is carried out under cGMP conditions, This product may be used for scientific research, but not for clinical or commercial use.Monoclonal Antibody manufacturers
website:http://www.therapeuticmab.com/monoclonal-antibody/
Features and Advantages:
NameBiosimilar of Cetuximab
CAS NO.205923-56-4
TypeWhole antibody
SourceChimeric (mouse/human)
TargetEGF receptor
CloneMonoclone
FormulaC6484H10042N1732O2023S36
Molecular Weight152 kDa
Antibody FormPurified immunoglobulin
Physical FormSolution
Place of OriginChina (Mainland)
StorageSealed and stored at -70±15℃, away from light
Specifications:
The concentration of The biosimilar of Cetuximab is 2 mg/mL, and the buffer formulation is consistent with the original preparation (Erbitux®).In addition, the product concentration and buffer system can be customized according to customer requirements. The annual production of the product is about 80-160kgs, the minimum order quantity is 1 gram.
Applications:
Cetuximab, the trade name Erbitux®, is a medication used to treat metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.
The formulation and filling of the biosimilar of Cetuximab bulk is carried out under cGMP conditions, This product may be used for scientific research, but not for clinical or commercial use.Monoclonal Antibody manufacturers
website:http://www.therapeuticmab.com/monoclonal-antibody/